DUBLIN – Poxel SA and development partner Sumitomo Dainippon Pharma Co. Ltd. are on track for a regulatory submission of their type 2 diabetes drug, Imeglimin, in Japan next year, after the first of three phase III trials delivered a positive result. Two other phase III studies are also due to read out this year, and the partners aim to have the drug on the market by 2021. Read More
PERTH, Australia – The Australian government's commitment of more than AU$1 billion (US$711 million) to support medical research in cancer and genomics sends the message to investors that the life sciences sector in Australia is sustainable, stakeholders said. Read More
HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) has started a phase IIb/III study for its surufatinib candidate, HMPL-012, an oral small-molecule angio-immuno kinase inhibitor that can simultaneously block tumor angiogenesis and immune evasion. Read More
HONG KONG – Asian drugmakers are increasingly embracing artificial intelligence (AI) technologies for drug discovery. The latest example is Japanese drug developer Ono Pharmaceutical Co. Ltd., which recently entered a partnership with U.S. AI-focused biotech firm Twoxar Inc. Read More
PERTH, Australia – Singapore-headquartered Cerecin Inc. is gearing up for a series of phase II trials in Australia of its lead compound, tricaprilin, for Alzheimer's disease. Read More
Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan, is among five partners investigating renal regenerative medicine, in a group that also includes: Bios Co. Ltd., of Tokyo; Pormedtec Co. Ltd., of Kawasaki City, Japan; the Jikei University School of Medicine in Tokyo; and Meiji University in Tokyo. Read More
